| ID | 1109 |
| Name of the vaccine | Plague Vaccine (by Greer Laboratories Inc.) |
| Microbe | Bacteria |
| Disease name | Plague |
| Name of bacteria | Yersinia pestis |
| Type of vaccine | Inactivated |
| Nucleic acid content | Circular DNA |
| Age | 18 to 61 years |
| Description of the vaccine | Plague vaccine. |
| Name of the manufacturer | Greer Laboratories Inc. |
| Name of the manufacturing country | United States |
| Year of manufacture | NA |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Three primary doses and booster doses (0.2 mL) each can be administered three times at 6-month intervals when continuous high risk for exposure. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Recommended for laboratory personnel who are routinely exposed and for persons in contact with the wild-rodent hosts or their fleas. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Local erythema, induration at the site of injection, malaise, headache, fever and lymphadenopathy. |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | Yes (enzootic from wild rodents and their fleas) |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=319&keywords= |
| Other name | NA |
| Additional Links | https://www.cdc.gov/mmwr/preview/mmwrhtml/00044836.htm
|